Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Sector
Medical - Devices
P/S (TTM)
4.3
Paragon 28, Inc. is a medical device company specializing in the development, manufacturing, and global distribution of advanced surgical systems tailored for foot and ankle procedures. Its comprehensive product portfolio encompasses a wide array of solutions: Plating Systems: This includes the Gorilla plating series, offering specific solutions for Lisfranc injuries, Lapidus procedures, lateral column corrections, calcaneus slides, and naviculocuneiform (NC) fusions. Complementary products like Baby Gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates, as well as Silverback plating systems, are also available. Precision Guidance Technology: The company provides sophisticated guidance systems to enhance accuracy in various operations, such as fusion procedures for bunion deformities, first tarsometatarsal arthrodesis, metatarsal osteotomy for bunion correction, medial column beaming for Charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. Screw Systems: Paragon 28 offers robust screw systems, including the Monster, Mini Monster, and Joust beaming lines, which are critical for applications like bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, and fracture repair. Joint Replacement Solutions: Their offerings extend to total ankle replacement with the APEX 3D systems, alongside total talus spacers designed to replace the talus bone that links the leg and foot. Bunion/Hallux Valgus Correction Systems: Specifically for bunion management, the company provides nail systems such as the Phantom intramedullary nail systems, targeting severe hallux valgus cases. Orthobiologics: A substantial part of their product line comprises various orthobiologics, including bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix. They also feature PRESERVE bone graft systems for homologous applications. Ancillary Products: The company further supplies soft tissue fixation systems, titanium sprayed polyetheretherketone (PEEK) implants, nitinol staple systems, stabilization solutions, and specialized curved instruments. Paragon 28 distributes its products to hospitals and ambulatory surgery centers through an established network of both direct sales representatives and stocking distributors. Founded in 2010, the company maintains its corporate headquarters in Englewood, Colorado.
www.paragon28.comNo one on the platform currently holds FNA.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2024-06-30 | 61,200 | $418.6K |
No one on the platform has traded FNA yet.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Analyst estimates unavailable for this ticker.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $333M | +14.1% | $-0.35 | $-0.42–$-0.28 | — | 5 |
| 2027 | $433M | +30.0% | $-0.24 | $-0.24–$-0.24 | — | 1 |
| 2028 | $516M | +19.2% | $-0.06 | $-0.06–$-0.06 | — | 2 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 3 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2025-05-14 | $-0.19 | $-0.18 | +5.3% |
| 2025-03-06 | $-0.12 | $-0.13 | -8.3% |
| 2024-11-12 | $-0.16 | $-0.15 | +6.3% |
| 2024-08-08 | $-0.15 | $-0.17 | -13.3% |
| 2024-05-08 | $-0.11 | $-0.18 | -63.6% |
| 2024-02-29 | $-0.10 | $-0.19 | -90.0% |
| 2023-11-08 | $-0.10 | $-0.10 | +0.0% |
| 2023-08-02 | $-0.09 | $-0.13 | -44.4% |
| $1.1B |
| — |
| ETHZEthzilla Corp. | $3.53 | +0.00% | $56M | — |
| GRCLGracell Biotechnologies Inc. | $10.25 | +0.05% | $198M | — |
Source: Financial Modeling Prep · peers by sector/industry
$NMTC $FNA bought by $ZBH for $13 per share. Give $NMTC some of those gains and you might be in their next acquisition for cheap. Shameless pumper.... 😉
View on StockTwits ↗$uuuu $fna Analyst price target for today.; stockoptions.fast-page.org
View on StockTwits ↗$FNA Shareholders approved the merger during telephone shareholders meeting. To be filed shortly with SEC. Likely to close next week.
View on StockTwits ↗$FNA Foot and ankle market looking hot. Zimmer Biomet acquisition is huge catalyst. Might start building a position here. Innovation pipeline looks strong and growth potential is massive. detailed article: https://beyondspx.com/article/paragon-28-inc-fna-redefining-the-foot-and-ankle-orthopedic-market
View on StockTwits ↗$FNA | SSI Weekly Newsletter: Mergers, Strategic Reviews, Liquidations, and Investment Updates "Paragon 28 is being acquired by Zimmer Biomet for $13/share plus a non-transferable CVR, with potential payout. Allakos is undergoing a strategic review, trading at net cash..." - Dalius Tauraitis (Special Situation Investments) Read more: https://www.smartkarma.com/insights/ssi-weekly-newsletter-mergers-strategic-reviews-liquidations-and-investment-updates
View on StockTwits ↗$FNA (+9.7% pre) $ZBH Zimmer Biomet acquires Paragon 28 at $13/share - inv https://ooc.bz/l/54283
View on StockTwits ↗$FNA found find through MOMO app. 5 year chart here got my attention :)
View on StockTwits ↗$FNA stockholders filed a claim against Paragon 28 for overstating inventory and downplaying costs, resulting in inaccurate financial statements. You can join this case to be notified about potential recovery: https://11thestate.com/cases/paragon-28-investor-suit
View on StockTwits ↗$FNA Paragon 28 stock, watch for a narrow range breakout above 11.22 at https://stockconsultant.com/?FNA
View on StockTwits ↗$FNA stockholders filed a claim against Paragon 28 for overstating inventory and downplaying costs, resulting in inaccurate financial statements. You can join this case to be notified about potential recovery: https://11thestate.com/cases/paragon-28-investor-suit
View on StockTwits ↗$FNA Paragon 28 stock, watch for a narrow range breakout, target 13 area, at https://stockconsultant.com/?FNA
View on StockTwits ↗$FNA stockholders filed a claim against Paragon 28 for overstating inventory and downplaying costs, resulting in inaccurate financial statements. You can join this case to be notified about potential recovery: https://11thestate.com/cases/paragon-28-investor-suit
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.